One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Gamida Cell Ltd. logo
Gamida Cell Ltd. GMDA

Gamida Cell Ltd. Financial Ratios 2021-2011 | GMDA

Annual Financial Ratios Gamida Cell Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- -4.9 -4.4 -6.8 - - - - - - -

EPS

- 1.7 1.2 10.5 27.6 32.9 - - - - -

EV (Enterprise Value)

- 283 M 144 M 359 M 641 K -9.84 M - - - - -

EBITDA per Share

- -1.43 -1.37 -1.34 - - - - - - -

EV/EBITDA

- -3.6 -2.4 -9.5 - - - - - - -

PEG

- -0.08 0.09 -0.04 - - - - - - -

P/B

- 3.6 4.3 14.5 - - - - - - -

P/CF

- -5.8 -3.7 -12.8 - - - - - - -

ROE %

- -73.63 -98.19 -214.41 - - - - - - -

ROA %

- -46.76 -49.95 -81.23 - - - - - - -

ROCE %

- -46.52 -84.08 -57.55 - - - - - - -

Current Ratio

- 6.0 5.0 9.3 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Gamida Cell Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- - - - - 0.33 0.36 - - 0.3 0.37 - - - -0.23 - - - 18.97 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - - - - - - - - - - - - - -0.42 - - - -14.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

- -42.72 -85.45 -118.67 -75.95 -100.30 -81.94 -68.91 -44.55 -44.55 8.81 58.02 58.02 29.01 -301.30 -660.61 -660.61 -330.31 -330.31 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

- -11.89 -23.78 -35.18 -23.29 -38.24 -41.29 -43.19 -28.24 -28.24 -2.16 22.27 22.27 11.14 -28.71 -79.70 -79.70 -39.85 -39.85 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

- -16.36 -32.71 -46.42 -30.07 -47.83 -49.24 -48.42 -30.65 -30.65 -37.42 -49.06 -49.06 -24.53 -60.34 -71.61 -71.61 -35.81 -35.81 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Gamida Cell Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 0.87 -7.57 % $ 77.9 M franceFrance
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.42 -1.64 % $ 11.6 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
$ 0.75 -9.23 % $ 4.11 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 7.6 -4.82 % $ 220 M usaUSA
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 0.38 -5.66 % $ 40.4 M canadaCanada
Lipocine Lipocine
LPCN
$ 1.47 -2.33 % $ 8.01 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
$ 1.25 -6.02 % $ 11.1 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.58 -2.98 % $ 148 M israelIsrael
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
$ 378.19 -4.68 % $ 8.48 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.2 -18.37 % $ 9.62 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 3.14 -9.13 % $ 188 M franceFrance
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 7.98 -1.97 % $ 642 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 39.21 1.76 % $ 44.9 B israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 60.77 -0.96 % $ 1.64 B usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
$ 25.52 -2.48 % $ 2.26 B usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.89 -5.56 % $ 227 M israelIsrael
Lantern Pharma Lantern Pharma
LTRN
$ 0.25 -13.67 % $ 2.72 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 1.71 -3.93 % $ 108 M usaUSA
Ocugen Ocugen
OCGN
$ 0.77 4.74 % $ 241 M usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
$ 0.35 -10.37 % $ 33.6 M canadaCanada
Minerva Neurosciences Minerva Neurosciences
NERV
$ 2.03 -4.25 % $ 17.2 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
$ 150.5 -3.89 % $ 15 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 26.12 -1.7 % $ 1.25 T franceFrance
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 8.12 -3.33 % $ 437 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.26 -5.45 % $ 207 M britainBritain
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
$ 6.99 -2.85 % $ 1.01 B usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 1.53 -8.68 % $ 555 M usaUSA
Moleculin Biotech Moleculin Biotech
MBRX
$ 7.73 -2.59 % $ 9.16 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 21.79 1.66 % $ 34.4 B japanJapan
Nurix Therapeutics Nurix Therapeutics
NRIX
$ 12.88 -5.29 % $ 1.12 B usaUSA
Nkarta Nkarta
NKTX
$ 1.14 1.34 % $ 84.3 M usaUSA
MacroGenics MacroGenics
MGNX
$ 1.97 -0.76 % $ 124 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
$ 121.72 -2.2 % $ 7.74 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
$ 37.8 -2.82 % $ 168 B danmarkDanmark
Marker Therapeutics Marker Therapeutics
MRKR
$ 1.1 -17.05 % $ 16.8 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
$ 15.62 -1.01 % $ 1.68 B usaUSA
Replimune Group Replimune Group
REPL
$ 19.07 -0.83 % $ 1.77 B usaUSA
NextCure NextCure
NXTC
$ 6.62 -2.43 % $ 35.2 M usaUSA
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 1.95 -7.82 % $ 217 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
$ 0.87 -33.79 % $ 45.7 M usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 553.08 -1.08 % $ 24.5 B usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
$ 7.0 -2.1 % $ 609 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 115.19 -3.52 % $ 9.73 B usaUSA
Oragenics Oragenics
OGEN
$ 0.16 -6.16 % $ 345 K usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
$ 2.2 -5.98 % $ 286 M usaUSA
Passage Bio Passage Bio
PASG
$ 3.94 9.14 % $ 12.6 M usaUSA
Vaxcyte Vaxcyte
PCVX
$ 55.37 -5.12 % $ 7.54 B usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
$ 16.11 1.26 % $ 2.76 B usaUSA
Precigen Precigen
PGEN
$ 4.21 1.08 % $ 1.32 B usaUSA